Vesugen
Lys-Glu-Asp (KED)
Vesugen is a synthetic tripeptide with experimental findings in cell cultures.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
The cited primary literature defines Vesugen as the tripeptide Lys-Glu-Asp. This study identity does not confirm salt form, purity or a commercial lot.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The sources concern cultured cells from human or animal tissues and molecular docking, not clinical vascular events.
- Peptides tissue-specifically stimulate cell differentiation during their agingLaboratory study2012
Khavinson VKh et al.
Accessed:
- Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during agingLaboratory study2014
Khavinson VKh et al.
Accessed:
Research gaps
- ·An abstract’s reference to earlier findings in older people is not a directly reviewed clinical source. Protection from heart attack or vascular aging is not established.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Research examined differentiation markers, Ki-67 and computationally modeled interaction with a promoter region.
- Peptides tissue-specifically stimulate cell differentiation during their agingLaboratory study2012
Khavinson VKh et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Controlled human exposure, pharmacokinetics, long-term toxicology, contraindications and interactions are absent.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·An abstract’s reference to earlier findings in older people is not a directly reviewed clinical source. Protection from heart attack or vascular aging is not established.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Peptides tissue-specifically stimulate cell differentiation during their agingLaboratory study2012
Khavinson VKh et al.
Accessed:
Sources
Sources checked: · Version 3
- Peptides tissue-specifically stimulate cell differentiation during their agingLaboratory study2012
Khavinson VKh et al.
Accessed:
- Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during agingLaboratory study2014
Khavinson VKh et al.
Accessed: